pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: License

Sep 26, 2023

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation

Sep 5, 2023

Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy

Jul 13, 2023

KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer

Jul 5, 2023

Pheon Therapeutics enters into license agreement with Biocytogen Pharmaceuticals

Jun 13, 2023

CORRECTING and REPLACING Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For the Treatment of Dry Eye Disease in Japan

Jun 1, 2023

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology

Jun 1, 2023

Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization

Jun 1, 2023

Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7/8 dual agonists

May 24, 2023

Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center

May 1, 2023

Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease

Apr 17, 2023

Pipeline Therapeutics Announces Global License and Development Agreement for Investigational Neuroscience Therapy, PIPE-307

Apr 5, 2023

Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets

Apr 5, 2023

Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders

Apr 4, 2023

Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer

Mar 6, 2023

Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001

Feb 23, 2023

AviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology

Feb 2, 2023

Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates

Jan 10, 2023

SIFI ANNOUNCES LICENSE AGREEMENT WITH AVANZANITE BIOSCIENCE FOR AKANTIOR

Jan 9, 2023

AmMax Bio Enters into an Exclusive Option Agreement with Evopoint Biosciences to License a Next Generation Antibody Drug Conjugate (ADC) for the Treatment of Solid Tumors

Jan 9, 2023

TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases

Jan 4, 2023

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

Jan 3, 2023

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

Dec 20, 2022

Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer

Nov 21, 2022

Blue Water Vaccines Announces Exclusive, Global License Agreement for Chlamydia Vaccine Candidate Development from The University of Texas Health San Antonio

Nov 17, 2022

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

Nov 8, 2022

Salipro Biotech enters into collaboration and license agreement with Sanofi to advance discovery programs

Oct 18, 2022

Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS T Cell Therapy for Neuroblastoma

Oct 18, 2022

Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovax™ Immunotherapy Platform

Oct 11, 2022

Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK

Oct 11, 2022

IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder

Sep 29, 2022

Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

Sep 12, 2022

Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region

Jul 26, 2022

ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement USA - English USA - English USA - English

Jul 12, 2022

LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate

Jul 12, 2022

Epic Bio, Founded by CRISPR Pioneer, Launches to Revolutionize Genetic Medicine With Epigenetic Engineering

Jun 28, 2022

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies

Jun 1, 2022

SciNeuro Pharmaceuticals Announces a License and Option Agreement with GSK to Progress Development of Novel Therapies for CNS Diseases

Jun 1, 2022

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology

May 19, 2022

Oviva Therapeutics, a Cambrian BioPharma *PipeCo, announces Seed Financing and Exclusive License with Massachusetts General Hospital to Develop Therapeutics to Extend Healthspan in Women

May 11, 2022

Blue Water Vaccines Announces Expanded License Agreement with St. Jude Children’s Research Hospital for Novel Bacterial Vaccine Platform

May 3, 2022

NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China

Apr 27, 2022

Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines

Apr 26, 2022

EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody in Switzerland

Apr 13, 2022

LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics

Mar 31, 2022

Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target

Mar 29, 2022

Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology

Mar 21, 2022

Nuance Pharma Announces License and Supply Agreement with Bavarian Nordic on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets

Mar 16, 2022

EdiGene Obtains Worldwide License from Boston Children’s Hospital to Methods and Compositions for Increasing Fetal Hemoglobin Levels to Treat Hemoglobinopathies

Mar 14, 2022

Catamaran Bio Expands Collaboration for CAR‑NK Cell Engineering with the University of Minnesota and Secures an Exclusive Patent License to Next Generation Manufacturing Technologies

Mar 7, 2022

University of Maryland, Baltimore (UMB) Grants GlycoMantra Exclusive License to Advance the Company's Therapeutic Pipeline

Mar 2, 2022

Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer

Mar 1, 2022

IASO Bio's Nanjing Manufacturing Facility Granted the Drug Manufacturing License for CAR-T Cell Therapy Products

Mar 1, 2022

Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease

Feb 17, 2022

Neumora Expands Precision Neuroscience Pipeline with Novel M4 Receptor Modulator Program Through Exclusive License Agreement with Vanderbilt University

Feb 17, 2022

Partner Therapeutics Announces Contract with U.S. Department of Defense for Advanced Development of Leukine to Treat Sulfur Mustard Gas (HD) Exposure

Feb 15, 2022

Trestle Biotherapeutics Announces License Agreement with Kumamoto University for Key Stem Cell Biology Technology for Regenerative Medicine

Feb 15, 2022

ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody

Feb 8, 2022

EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs

Jan 19, 2022

SiteOne Therapeutics Announces Collaboration and License Agreement with Vertex Pharmaceuticals to Advance NaV1.7 Inhibitors for the Treatment of Pain

Jan 10, 2022

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

Jan 10, 2022

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct USA - English USA - English

Jan 7, 2022

Neurimmune enters into a collaboration and license agreement with AstraZeneca to develop and commercialize NI006

Jan 6, 2022

Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor

Jan 5, 2022

Enteris BioPharma Highlights 2021 Achievements and 2022 Outlook

Jan 4, 2022

Genmab and Synaffix Enter into License Agreement for ADC Technology

Dec 22, 2021

Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China

Dec 22, 2021

AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPEAT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

Dec 13, 2021

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

Dec 2, 2021

HUYABIO Announces the Exclusive License of the KRAS Inhibitor from Shanghai Jemincare Pharmaceutical

Nov 30, 2021

Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO USA - English USA - English Brazil - Português Latin America - español

Nov 16, 2021

Recbio Receives Pharmaceutical Production License from Jiangsu Medical Products Administration for Production of COVID-19 Vaccine

Nov 9, 2021

HUYABIO Announces the Exclusive License of the Wee1 Inhibitor from Shanghai Pharmaceuticals

Nov 3, 2021

Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics

Oct 14, 2021

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Oct 12, 2021

Salipro Biotech enters into a collaboration and license agreement with AbCellera for access to the Salipro Platform for antibody discovery against GPCRs, ion channels, and transporters

Oct 5, 2021

Newly Formed Lanier Biotherapeutics Enters into License Agreement with Alloy Therapeutics

Sep 28, 2021

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

Sep 28, 2021

UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions

Sep 27, 2021

Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions

Sep 22, 2021

OncoNano Medicine Announces Expanded Research Collaboration With UT Southwestern Medical Center to Advance Development of New Cancer Therapies

Sep 16, 2021

Tarveda Therapeutics and SciClone Pharmaceuticals Expand Partnership by Entering into a License Agreement for HSP90-PI3K Miniature Drug Conjugates in Greater China

Sep 9, 2021

Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline

Sep 8, 2021

AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan

Sep 1, 2021

Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)

Aug 31, 2021

Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research

Aug 19, 2021

Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology

Aug 17, 2021

ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement

Aug 16, 2021

ADDING MULTIMEDIA Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy Technology

Aug 16, 2021

Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy Technology

Jul 28, 2021

DiosCURE Announces Exclusive Worldwide License Agreement for Best-in-Class Nanobodies Against COVID-19

Jul 28, 2021

Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers

Jul 26, 2021

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement

Jul 13, 2021

ExCellThera and Astellas enter into a license for the use of molecule UM171 in the field of pluripotent stem cells

Jul 13, 2021

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement USA - English USA - English

Jul 6, 2021

Tetherex Pharmaceuticals Signs Exclusive Worldwide License with Mayo Clinic for Development and Commercialization of a Novel Single-Cycle Adenovirus Vaccine Platform

Jul 6, 2021

Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma

Jun 30, 2021

ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement

Jun 28, 2021

Innovent Announces License Agreement with Synaffix in an ADC Technology Deal

Jun 24, 2021

Catamaran Bio and Bio-Techne Announce Expanded Collaboration for CAR‑NK Cell Manufacturing Technologies

Jun 24, 2021

Bio-Techne and Catamaran Bio Announce Expanded Collaboration for CAR-NK Cell Manufacturing Technologies

Jun 22, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE drug delivery technology to enable development of “ultra long-acting” medicines for HIV

Jun 22, 2021

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE drug delivery technology to enable development of "ultra-long-acting" medicines for HIV

Jun 21, 2021

BioAxone BioSciences Announces License of Cerebral Cavernous Malformations Drug Candidate BA-1049 and Portfolio of Rho Kinase Inhibitors to Neurelis

Jun 16, 2021

Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche

Jun 15, 2021

OncoMyx Announces Exclusive Option to License Intellectual Property Rights for Myxoma Virus Technology from University of Florida

Jun 2, 2021

Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets

May 31, 2021

AnHeart Therapeutics and Innovent Biologics Announce Exclusive License Agreement for Taletrectinib in Greater China

May 27, 2021

ONK Therapeutics Secures Exclusive Global License to Patent for CISH Knockout in NK Cells for the Treatment of Cancer, from Australia’s WEHI

May 17, 2021

Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB

May 13, 2021

Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India

May 12, 2021

ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement

May 1, 2021

Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement

Apr 28, 2021

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

Apr 26, 2021

Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

Apr 26, 2021

OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market

Apr 20, 2021

Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

Apr 20, 2021

Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform

Apr 19, 2021

ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement

Apr 15, 2021

Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Bevacizumab Biosimilar in the Russian Federation

Apr 13, 2021

Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol

Apr 12, 2021

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis

Apr 8, 2021

Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6 Antibodies for Gynecologic Cancer Therapeutic Program

Mar 31, 2021

Evive Biotech Submits Biologics License Application to US FDA for Ryzneuta(TM)

Mar 30, 2021

ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China

Mar 25, 2021

Bright Peak Therapeutics Inc. and Ajinomoto Co., Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines

Mar 23, 2021

Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

Mar 18, 2021

Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates

Mar 18, 2021

ONK Therapeutics Strengthens its Cell Therapy Manufacturing Process with License for EBV-LCL Feeder Cell Line from NIH to Enhance NK Cell Expansion

Mar 17, 2021

FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies

Mar 10, 2021

Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech

Mar 9, 2021

ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement

Mar 2, 2021

ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China

Mar 2, 2021

Wugen Announces Exclusive License Agreement With HCW Biologics For Cell Therapies to Treat Cancer

Mar 1, 2021

LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich's Ataxia Gene Therapy Program (LX2006)

Mar 1, 2021

Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

Feb 23, 2021

ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement

Feb 22, 2021

Wugen Announces Exclusive License Agreement for their Memory Natural Killer (NK) Cell-based Therapy Program with Washington University in St. Louis

Feb 16, 2021

New York University Professor of Chemistry Dr. Kent Kirshenbaum Named Chief Scientific Officer at Maxwell Biosciences

Feb 16, 2021

ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement

Feb 11, 2021

Ensoma Announces Strategic Collaboration with Takeda to Accelerate Next-Generation In Vivo Gene Therapies

Feb 9, 2021

Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China

Feb 3, 2021

AuraVax Therapeutics Enters into Exclusive License Agreement with the University of Houston for Intranasal Vaccine and Therapeutics Technology Platform

Feb 2, 2021

Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries

Feb 1, 2021

Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles

Jan 28, 2021

Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies

Jan 25, 2021

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT (Siltuximab for Injection) in China

Jan 13, 2021

AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform

Jan 12, 2021

POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment

Jan 11, 2021

Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

Jan 11, 2021

Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARROTM) in Greater China

Jan 7, 2021

Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs

Jan 7, 2021

IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain

Dec 21, 2020

HitGen Announces License Agreement With Merck and Co., Inc., Kenilworth, NJ USA to Access Compounds for Potential Development of a Novel Class of Drugs

Dec 17, 2020

Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement

Dec 17, 2020

Cadent Therapeutics Enters Agreement to be Acquired by Novartis

Dec 17, 2020

ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline

Dec 14, 2020

Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials

Dec 10, 2020

Braeburn Announces Arbitration Determination that It Did Not Materially Breach Its License Agreement with Camurus AB

Dec 10, 2020

LIPAC Oncology Announces Major Partnering Milestone Achieved in its License Agreement with Huons Co., Ltd.

Dec 1, 2020

Vivlion GmbH Signs Worldwide License Agreement With ERS Genomics for CRISPR/Cas9 Patent Portfolio

Nov 30, 2020

Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a Novel Anti-Inflammatory

Nov 17, 2020

Tris Pharma and Medison Pharma Announce Exclusive License Agreement to Commercialize Tris' Quillivant XR in Israel USA - English USA - English

Nov 17, 2020

Tris Pharma and Medison Pharma Announce Exclusive License Agreement to Commercialize Tris' Quillivant XR in Israel

Nov 16, 2020

Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency

Nov 11, 2020

Vor Biopharma Announces Exclusive License of Clinical-Stage CD33 CAR-T from National Cancer Institute

Nov 10, 2020

TScan Therapeutics Announces Partnership with QIAGEN to Develop T Cell-Based Laboratory Test for Comprehensive COVID-19 Immune Response

Nov 10, 2020

Prestige Biopharma and Teva Israel Announce License and Supply Agreement to Commercialize Prestige's Trastuzumab Biosimilar (Tuznue™) in Israel

Nov 10, 2020

Emmaus Life Sciences Submits Temporary License Application in Bahrain for Endari USA - English USA - English

Nov 10, 2020

Renew Biopharma and Algae-C Announce License Agreement for Best-in-Class Engineered Enzymes

Nov 5, 2020

TFF Pharmaceuticals and Felix Biotechnology Sign Letter of Intent for a Collaboration, Development and License Agreement

Oct 30, 2020

Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA and OTX-TIC in Asia

Oct 29, 2020

L'Oréal signs license agreement with Dutch biotech Micreos, world leader in targeted bacterial biotechnology English Netherlands - English Français Deutsch Nederland - Nederlands

Oct 29, 2020

L'Oréal signs license agreement with Dutch biotech Micreos, world leader in targeted bacterial biotechnology USA - English USA - Nederlands Nederland - English USA - Français USA - Français USA - Deutsch USA - Deutsch Nederland - Nederlands

Oct 29, 2020

L'Oréal signs license agreement with Dutch biotech Micreos, world leader in targeted bacterial biotechnology Nederland - English USA - English USA - Français USA - Deutsch Nederland - Nederlands

Oct 28, 2020

Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix (pitolisant)

Oct 28, 2020

Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications

Oct 21, 2020

EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi and Submits Market Authorization Application in Switzerland

Oct 21, 2020

Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19

Oct 21, 2020

Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio

Oct 15, 2020

CORRECTING and REPLACING Entos Pharmaceuticals Announces Launch of US-Based Spinout Company Aegis Life, Inc. to Support its Global Vaccine Commercialization Strategy

Oct 14, 2020

Dyno Therapeutics Enters Collaboration and License Agreement With Roche to Develop Next-Generation AAV Gene Therapy Vectors for CNS Diseases and Liver-Directed Therapies

Oct 12, 2020

AuraVax Therapeutics Enters into Exclusive License Option Agreement with the University of Houston for Intranasal Vaccine Platform

Sep 23, 2020

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

Sep 22, 2020

ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for Neffy™ (ARS-1; epinephrine nasal spray)

Sep 15, 2020

Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™

Sep 3, 2020

Lodo Therapeutics Acquires Hibiskus BioPharma And Licenses Rights To Novel Proteasome Inhibitors

Aug 17, 2020

Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program

Aug 17, 2020

LG Chem Life Sciences and TransThera Biosciences Announce License Agreement for Potential Treatment of NASH and Other Chronic Inflammatory Conditions

Aug 13, 2020

UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.

Aug 12, 2020

Novome Biotechnologies Expands Therapeutic Focus and Platform Capabilities with Acquisition of Preclinical Projects and Intellectual Property from Caribou Biosciences and License to CRISPR-Cas9 Foundational Patent Portfolio

Aug 6, 2020

ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies

Aug 4, 2020

ZYUS Life Sciences Receives Medical Sales License from Health Canada

Jul 29, 2020

Ridgeback Biotherapeutics LP Announces Priority Review of Biologics License Application for ansuvimab Ebola Treatment

Jul 28, 2020

Terns Pharmaceuticals and Hansoh Pharma Announce Collaboration and License Agreement for TRN-000632 in Greater China

Jul 20, 2020

JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China

Jul 15, 2020

AnHeart Therapeutics Announces License Agreement with NewG Lab for Taletrectinib Rights in Korea

Jul 9, 2020

Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada USA - English France - Français

Jun 23, 2020

Aligos Therapeutics and Emory University Announce Expanded License Agreement and Ink Agreement for Chronic Hepatitis B Collaboration

Jun 16, 2020

Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001

Jun 9, 2020

Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly

Jun 8, 2020

Aerami Therapeutics Signs a Global License Agreement with Vectura Group, Adding an Inhaled Therapy for Patients with Pulmonary Arterial Hypertension to Their Pipeline

Jun 5, 2020

UCB Acquires Engage Therapeutics: Staccato Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

Jun 3, 2020

PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas

May 11, 2020

Dyno Therapeutics Announces Ocular Collaboration with Novartis to Develop Improved Gene Therapies with AAV Vectors based on AI Technology

May 8, 2020

Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform

May 7, 2020

Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement

Apr 23, 2020

EpimAb Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Research Collaboration and License Agreement on Novel Bispecific Target Combinations

Apr 7, 2020

EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries USA - English Deutschland - Deutsch

Apr 2, 2020

ERS Genomics and Axxam Announce CRISPR/Cas9 License Agreement to Enhance Discovery Services

Mar 30, 2020

LifeMax Launches AmMax Bio Following The License Of Worldwide Rights to a Clinical Stage Orphan Asset From Amgen

Mar 26, 2020

CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries

Mar 23, 2020

NeoImmuneTech Enters into Exclusive License Agreement with Ubix Therapeutics to Develop Drug Candidates Including T Cell Suppressor Blockade

Mar 19, 2020

Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China

Mar 18, 2020

HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies

Mar 16, 2020

Medivir and Tango Therapeutics Sign License Agreement for Preclinical Asset

Mar 16, 2020

Bridge Medicines Enters Exclusive License Agreement with The Rockefeller University for Novel Epigenetic Leukemia Program

Mar 10, 2020

POINT Biopharma and SCINTOMICS Announce License Agreement

Feb 25, 2020

Arecor Achieves Second License Milestone Payment From Global Pharmaceutical Partner

Feb 25, 2020

Trianni, Inc. Announces License Agreement with Artizan Biosciences, Inc. for the Trianni Mouse

Feb 11, 2020

ERS Genomics and Aelian Biotechnology Announce CRISPR/Cas9 License Agreement Enabling Aelian's Unique Screening Platform

Jan 15, 2020

Bloom Science Granted Exclusive Option to License Microbiome-Based Technology for the Development of Novel Treatments for Multiple Neurological and Oncology Conditions

Jan 13, 2020

Ligand Enters into OmniAb Platform License Agreement with Pandion Therapeutics

Jan 13, 2020

Horizon Discovery Signs Collaboration and License Agreement with Mammoth Biosciences

Jan 13, 2020

Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab

Jan 7, 2020

Synaffix announces expansion of license agreement with Shanghai Miracogen Inc. to a second ADC candidate

Jan 7, 2020

Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies

Dec 19, 2019

Turnstone Biologics Announces Global Collaboration and License Agreement with Takeda to Develop Novel Viral Immunotherapies

Dec 17, 2019

HitGen and MTPC Enter Into License Agreement

Dec 11, 2019

Forendo Pharma Signs Important License and Collaboration Deal with Leading Pharma Company

Dec 9, 2019

Gemini Therapeutics and Avitide Enter Into Exclusive License Agreement

Dec 3, 2019

GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio Compound

Nov 21, 2019

Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer

Nov 21, 2019

AN2 Therapeutics Launches with $12 Million in Series A Funding and Announces a Strategic Partnership with Brii Biosciences

Nov 18, 2019

ITM and CIRC Sign Technology License Agreement for the Production and Distribution of Medical Radioisotopes in China

Nov 12, 2019

LEO Pharma Exercises Option with HitGen to License Compounds for Development of Novel Class of Drugs in Dermatology

Nov 6, 2019

Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

Oct 31, 2019

Beam Therapeutics Announces Collaboration and Exclusive License Agreement with Prime Medicine for Prime Editing Technology

Oct 22, 2019

Qpex Biopharma and Brii Biosciences Enter Into a Strategic Collaboration to Develop and Commercialize Antibiotics for Drug-Resistant Infections in China

Oct 22, 2019

Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment USA - English France - Français Deutschland - Deutsch España - español

Oct 17, 2019

Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology

Oct 15, 2019

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

Oct 1, 2019

Tmunity Announces Exclusive License and Research Collaboration with Children’s Hospital of Philadelphia to Advance GPC2 CAR-T Cell Therapy for Neuroblastoma

Aug 27, 2019

Viela Bio Announces U.S. FDA Accepts for Review Inebilizumab Biologics License Application for Neuromyelitis Optica Spectrum Disorder

Aug 27, 2019

Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers

Aug 21, 2019

Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence Oral Formulation Technology

Aug 1, 2019

Pfenex and Arcellx Announce a Development, Evaluation and License Agreement

Aug 1, 2019

Pfenex and Arcellx Announce a Development, Evaluation and License Agreement

Jul 17, 2019

Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss

Jul 16, 2019

Avion Pharmaceuticals, LLC, and ROMEG Therapeutics, LLC, finalize partnership agreement to license and commercialize Gloperba, a prophylactic treatment of gout in adults

Jul 9, 2019

Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to Optimize Ocular Oncology Drug Delivery

Jun 13, 2019

EffRx Pharmaceuticals Signs Exclusive License Agreement with Pharmaxis for the Registration and Commercialization of Bronchitol® in Switzerland

Jun 13, 2019

EffRx Pharmaceuticals Signs Exclusive License Agreement with Pharmaxis for the Registration and Commercialization of Bronchitol in Switzerland

May 31, 2019

Beam Therapeutics and Bio Palette Announce Exclusive License Agreements for Base Editing Technologies

May 16, 2019

Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program

May 10, 2019

HitGen and Kaken Enter Into License Agreement

May 1, 2019

Tmunity and UC San Francisco Announce Exclusive License and Research Collaboration to Advance TCR T Cell Therapies for Pediatric Cancers

Apr 24, 2019

ADC Therapeutics and Adagene Announce License Agreement

Apr 10, 2019

Synaffix Announces License Agreement Worth up to $125 Million with Leading Chinese ADC Developer, Shanghai Miracogen

Mar 28, 2019

StrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological Diseases

Mar 14, 2019

Targovax Grants Zelluna Immunotherapy an FTO License to Intellectual Property Relating to Mutant Ras T Cell Receptor Technology

Mar 5, 2019

Numab Announces Entry into a License Agreement With Intarcia for Anti-Inflammatory ND016

Mar 4, 2019

BlackThorn Therapeutics and Total Brain Announce Exclusive License Agreement to Enhance Patient Selection and Development of Targeted Therapies for Neurobehavioral Disorders

Feb 20, 2019

Knight Therapeutics and Triumvira Immunologics Triumphantly Announce Secured Bridge Loan and License Agreement

Feb 20, 2019

Morphocell Technologies Signs Exclusive License for the Commercialisation of Innovative Stem Cell-Derived Encapsulated Liver Tissue Technology

Feb 12, 2019

Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing

Feb 4, 2019

Trevi Therapeutics Announces License Agreements for use of Nalbuphine for the Treatment of Levodopa-Induced Dyskinesia (LID) in Parkinson’s Disease

Jan 31, 2019

Inotrem Announces an Extension of Its License Agreement for the Biomarker Soluble TREM-1 to Cardiovascular Diseases

Jan 24, 2019

Origenis GmbH Announces Global License and Collaboration Agreement with Expansion Therapeutics for Novel Therapies Targeting RNA-mediated Diseases

Jan 18, 2019

Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New Settings

Jan 8, 2019

Ascentage Pharma Announces New License with Unity Biotechnology

Jan 4, 2019

Synaffix Announces License Agreement with Mersana Therapeutics for the Use of its GlycoConnect™ Site-Specific ADC Technology

Jan 4, 2019

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

Jan 4, 2019

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets USA - English USA - español USA - Deutsch USA - Français

Jan 3, 2019

Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics

Jan 3, 2019

Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology

Jan 2, 2019

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead

Dec 17, 2018

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies

Dec 6, 2018

VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences for up to $129 Million plus Royalties to Develop a Functional Cure for Hepatitis B

Nov 28, 2018

HOOKIPA and DarwinHealth Enter into a Research Collaboration and License Agreement to Discover and Prioritize Novel Immunogenic, Tumor-Specific Cryptic Antigens

Nov 26, 2018

Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer

Nov 26, 2018

CBT Pharmaceuticals and Zhejiang Bossan Pharmaceutical Enter into a Collaboration and License Agreement to Develop Combination Cancer Treatments

Nov 19, 2018

GEn1E Lifesciences Adds to Development Pipeline with Exclusive Option to License University of Maryland, Baltimore’s MUC1-Ecto-Domain Anti-Bacterial Agent

Nov 14, 2018

Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement

Nov 13, 2018

WUGEN Announces Exclusive License Agreement for CAR-T Therapy Technologies from Washington University in St. Louis

Oct 30, 2018

G3 Pharmaceuticals Signs Exclusive License and Option Agreement for Treating Diastolic Heart Failure (HFpEF) by Inhibiting Galectin-3.

Oct 17, 2018

GEn1E Lifesciences Granted Exclusive Option to License University of Maryland, Baltimore’s Selective P38 Kinase Inhibitor

Oct 16, 2018

ERS Genomics and Syngulon Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Industrial Applications

Oct 9, 2018

GenAhead Bio and ERS Genomics Enter into CRISPR/Cas9 License Agreement

Oct 4, 2018

Axcelead Drug Discovery Partners and ERS Genomics Enter into CRISPR/Cas9 License Agreement

Oct 2, 2018

GO Therapeutics Enters into a License Agreement with Roche for New Glycotargeting Bispecific Cancer Treatment

Oct 1, 2018

Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors

Oct 1, 2018

Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors USA - English USA - Deutsch USA - español USA - Français

Sep 27, 2018

Decibel Therapeutics and Oricula Therapeutics Announce Exclusive License for ORC-13661 in Phase 1 Development for Hearing and Balance Protection

Sep 25, 2018

VenatoRx Pharmaceuticals and Everest Medicines II Limited Announce Exclusive License Agreement for cefepime/VNRX-5133

Sep 17, 2018

Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate

Sep 17, 2018

ITM and Merck KGaA Sign Research Evaluation and Option Agreement to Develop Folate Receptor Targeted Radionuclide Therapy

Sep 10, 2018

CCAB And Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates

Sep 7, 2018

BDD Pharma and Cingulate Therapeutics Announce License Agreement With OralogiK™ Enabled Triple Pulse Products

Sep 4, 2018

Turnstone Biologics and the La Jolla Institute for Allergy and Immunology Enter into Strategic Collaboration for Personalized Neoantigen Immunotherapies

Aug 20, 2018

Bio-Thera Solutions Announces China National Drug Administration Acceptance of Biologics License Application for Proposed Biosimilar to Humira® (Adalimumab)

Aug 20, 2018

Bio-Thera Solutions Announces China National Drug Administration Acceptance of Biologics License Application for Proposed Biosimilar to Humira (Adalimumab)

Aug 13, 2018

Cancer Prevention Pharmaceuticals Completes North American Licensing Deal with Mallinckrodt

Aug 6, 2018

Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers

Jul 30, 2018

HitGen Extends and Expands Research Collaboration and License Agreement With MSD To Build and Screen Novel DNA-Encoded Libraries

Jul 19, 2018

Theramex to Exclusively License Intrarosa In Europe, Australia, Russia and The Ukraine from Endoceutics USA - English USA - English Deutschland - Deutsch

Jul 17, 2018

Eureka Therapeutics Announces that Boehringer Ingelheim is Exercising an Option to License Novel TCR Mimic (TCRm) Antibodies

Jul 10, 2018

Adlai Nortye Announce Global License Agreement for Buparlisib (BKM120) USA - English France - Français España - español Deutschland - Deutsch

Jul 10, 2018

Adlai Nortye Announce Global License Agreement for Buparlisib (BKM120) Deutschland - Deutsch España - español USA - English France - Français USA - English

Jun 26, 2018

Skyhawk Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing Modifiers using Skyhawk's STAR* Technology Platform

Jun 26, 2018

Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China

Jun 21, 2018

MaaT Pharma and Lutech Sign Licensing Agreement on Microbiome Therapy for Graft-vs-Host Disease

Jun 11, 2018

Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology From National University of Singapore and St. Jude Children’s Research Hospital

Jun 5, 2018

Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B

Jun 4, 2018

Denovo Biopharma Acquires Exclusive License of Novel Application of DB102 in the Treatment of Pulmonary Arterial Hypertension

Jun 4, 2018

Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China

May 30, 2018

Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence

May 30, 2018

Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory Indications

May 30, 2018

Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine For Opioid Dependence

May 24, 2018

Bloom Science Launches to Develop Neuroprotective Epilepsy Treatments in Orphan Indications with Exclusive Technology License from UCLA

May 23, 2018

HitGen Announces Research Collaboration and License Agreement with Simcere

May 20, 2018

Mundipharma and Endoceutics to Exclusively License Intrarosa™ (Prasterone) in MEA Region USA - English France - Français

Apr 11, 2018

LEUKOCARE and Boehringer Ingelheim Enter into a Long-Term Agreement in the Field of Animal Health

Mar 22, 2018

CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody

Mar 5, 2018

MyBiotics Signs Second Option to License Agreement with Ferring Holding for Microbiome-Based Therapies

Feb 13, 2018

MOLOGEN Signs License Deal for China and Global Co-Development Agreement with ONCOLOGIE for Lead Compound lefitolimod

Dec 13, 2017

Arrakis Therapeutics Announces Exclusive License to RNA-targeted Small Molecule Technology from the University of Pennsylvania

Dec 12, 2017

Palleon Pharmaceuticals Signs Exclusive License Agreement with King’s College London for Intellectual Property Related to Glycoimmune Checkpoints to Treat Cancer

Dec 6, 2017

Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments

Nov 10, 2017

ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and Services

Nov 9, 2017

Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

Oct 18, 2017

Visterra Announces Research Collaboration, Exclusive License, and Option Agreement for Infectious Diseases with Vir Biotechnology

Oct 18, 2017

Pharmazz, Inc. has received exclusive license to U.S. patent for treatment of opioid tolerance and pain management

Oct 11, 2017

ADC Therapeutics Triggers Second Target-Specific License to Synaffix ADC Platform under Existing Agreement

Oct 3, 2017

BlueRock Therapeutics and Universal Cells Enter Collaboration and License Agreement to Generate Gene-Edited iPS Cell Lines

Sep 27, 2017

Casebia Therapeutics Announces License and Collaboration Agreements with Seattle Children’s Research Institute

Sep 20, 2017

Glythera and IONTAS Enter into License Agreement for the Development of Multiple Antibodies for Next-Generation Antibody Drug Conjugates

Sep 13, 2017

Onxeo Grants Exclusive Worldwide License of Validive Developed for the Treatment of Oral Severe Mucositis to Monopar Therapeutics

Sep 12, 2017

HanAll Biopharma and Harbour BioMed Sign Collaboration and License Agreement to Develop Two Novel Biologic Therapies in Greater China

Sep 11, 2017

Airway Therapeutics, LLC Obtains License on Glycotope Cell Line

Sep 7, 2017

Humacyte Completes Patient Enrollment for Phase III Clinical Trial of Human Acellular Vessel

Sep 6, 2017

Rebiotix Appoints Edward S. Burd, Ph.D., to Head of Regulatory Affairs

Aug 29, 2017

Dance Biopharm Announces Buyback of Dance-501 Asia License from Harmony Plus Holdings

Aug 22, 2017

Grid Therapeutics Signs Exclusive License Agreement to Develop a Novel Immuno-Oncology Antibody

Jul 20, 2017

AMO Pharma Enters into Development and License Agreement with Numedicus Limited for Rett Syndrome Program

May 18, 2017

Immunomic Therapeutics and TRIANNI Sign License Agreement for The Trianni Mouse™

May 18, 2017

HitGen and Pfizer Enter Research Collaboration and License Agreement to Build and Screen Novel DNA-Encoded Libraries

May 15, 2017

Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV)

May 10, 2017

Caribou Biosciences Announces Grant of a Key CRISPR-Cas9 Genome Editing Patent in Europe

May 5, 2017

Finch Therapeutics and Takeda Announce Global Collaboration to Develop Microbiome Therapeutics in Inflammatory Bowel Disease (IBD)

Apr 25, 2017

EpiVax Signs First Commercial License for Tregitope Technology Deutschland - Deutsch España - español France - Français USA - English

Apr 24, 2017

Denovo Biopharma Obtains Exclusive License To Liafensine From AMRI

Apr 3, 2017

CCAB Signs Collaboration and License Agreement With Pionyr Immunotherapeutics Inc. to Discover Antibody Drug Development Candidates

Mar 14, 2017

CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte

Feb 28, 2017

Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene

Feb 27, 2017

Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies

Feb 14, 2017

AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)

Jan 30, 2017

Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic

Jan 5, 2017

Biogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN(R) half-life extension technology

Dec 20, 2016

Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors

Dec 13, 2016

Castle Creek Pharmaceuticals Announces License of Exclusive U.S. Rights for Arlevert from Hennig Arzneimittel GmbH

Dec 7, 2016

Cognito Therapeutics Launched with Exclusive License to Promising Alzheimer’s Research from The Massachusetts Institute of Technology

Nov 2, 2016

ERS Genomics and Knudra Transgenics Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Model-Organisms

Oct 27, 2016

ERS Genomics and Evolva Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications

Oct 24, 2016

Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to Include New Combination Product for Pain and Nausea

Oct 24, 2016

Camurus AB: Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to Include New Combination Product for Pain and Nausea

Oct 24, 2016

Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to include New Combination Product for Pain and Nausea

Oct 20, 2016

SOTIO and NBE Therapeutics sign license agreement

Oct 4, 2016

Catalent Biologics and Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag™ ADC to Clinic

Sep 19, 2016

Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform

Sep 16, 2016

Ligand Enters OmniAb License Agreement with TeneoBio, Inc.

Sep 15, 2016

OncoImmune Announces Option and License Agreement with Pfizer Inc.

Aug 16, 2016

Avion Pharmaceuticals, LLC Renews Ongoing Partnership With Gnosis, S.P.A., To License Quatrefolic, Body-ready Folate, Through Patent Life Of 2028

Apr 28, 2016

BioQ Pharma Expands U.S. License and Supply Agreement to Commercialize Third Ready-to-Use Infusion Product

Mar 30, 2016

Vedanta Biosciences Announces License Agreement with RIKEN and other Japanese Institutions for New Immune Boosting Microbiome Technology

Jan 28, 2016

Agilis Biotherapeutics and National Taiwan University Enter into Worldwide, Exclusive License Agreement for the Gene Therapy Treatment of AADC Deficiency

Jan 21, 2016

Philogen Announces Exercise of Options Within the License Agreement With Pfizer Inc. for the Development and Potential Commercialization of Multiple Antibody Drug Conjugates (ADCs) and Targeted Technologies

Jan 11, 2016

Lycera Announces Celgene Has Exercised its Option to License Portfolio of Ex Vivo RORgamma Agonist Compounds under Global Strategic Collaboration

Jan 7, 2016

Eureka Therapeutics Announces Exclusive License Agreement between Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Use of a Novel, Fully-Human MUC16 Binder in CAR T Cell Immunotherapy

Dec 22, 2015

Forge Therapeutics Receives Exclusive License for Intellectual Property on Metalloprotein Inhibitors from University of California, San Diego

Dec 9, 2015

Rhizen Pharmaceuticals Announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3K-delta gamma Inhibitor

Dec 2, 2015

APR Applied Pharma Research S.A. and Eris Pharmaceuticals (Australia) Pty Ltd. Announce the Signature of a License Agreement for the Distribution and Marketing of the HALYKOO Line in Australia and New Zealand

Nov 24, 2015

EDELRIS Announce Exclusive License Agreement with ENYO Pharma

Nov 9, 2015

Morphotek, Inc. Announces A License Agreement With Blaze Bioscience, Inc. For The Development Of Novel Oncology Imaging Technology

Oct 20, 2015

Nimbus Therapeutics Announces Global License Agreement with Genentech

Sep 17, 2015

Agilis Biotherapeutics and the University of South Florida Enter into Worldwide, Exclusive License Agreement for the Treatment of Cognitive Disorders Using Reelin-Based Therapies

Aug 12, 2015

Checkmate Pharmaceuticals Debuts with $20 Million Series A Investment for Development of Novel Immuno-Oncology Product Platform

Aug 11, 2015

Poseida Therapeutics, Inc. Announces Worldwide License Agreement With Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) Therapies

Jul 15, 2015

CANbridge Acquires License for Apogenix’s APG101 Onco-Immunotherapy in Glioblastoma for China

Jun 15, 2015

APR Applied Pharma Research S.A. and Amicus S.A. Announce the Signature of a License Agreement for the Distribution and Marketing of the HALYKOO Line in the Balkan Region

May 13, 2015

Agilis Biotherapeutics and the University of South Florida Enter Into Worldwide, Exclusive License Agreement for Angelman Syndrome Gene Therapy

May 6, 2015

POXEL and ENYO Pharma Sign License Agreement for POXEL’s FXR Agonist Program

Apr 15, 2015

SELLAS Life Sciences Group and TrojanTec Sign Exclusive License Agreement for Global Rights on Development and Commercialization of Innovative TR-1 Anti-Cancer Antennapedia Technology

Mar 31, 2015

X-Chem and Navitor Pharmaceuticals Enter into License Agreement on Novel Small Molecules Targeting mTORC1 Activation

Feb 4, 2015

Third Rock Ventures Launches REVOLUTION Medicines with $45 Million Series A to Redesign Evolution’s Products to Treat Serious Diseases

Jan 29, 2015

Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis

Jan 14, 2015

3SBio Signs Exclusive Patent License Agreement for DIG-KT, a Bi-Specific mAb targeting VEGFR2 and Tie-2 with PharmAbcine

Jan 13, 2015

Vedanta Biosciences Announces License Agreement with Janssen and Johnson & Johnson Innovation for Microbiome Pharmaceutical Candidate for Inflammatory Bowel Disease

Jan 13, 2015

Janssen and Johnson and Johnson Innovation Announce License Agreement with Vedanta Biosciences for Microbiome Pharmaceutical Candidate for Inflammatory Bowel Disease

Jan 13, 2015

National Research Council of Canada and KalGene Pharmaceuticals announce license agreement for the development of novel Alzheimer's therapeutics

Dec 22, 2014

EpiVax, Inc. enters license agreement with Novozymes Biopharma to advance pioneering treatment of autoimmune diseases

Dec 18, 2014

Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics

Dec 18, 2014

Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics

Nov 20, 2014

Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting buprenorphine injectables for the treatment of opioid dependence and pain

Nov 20, 2014

Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting buprenorphine injectables for the treatment of opioid dependence and pain Sverige - English USA - English

Nov 18, 2014

3SBio Signs Exclusive Patent License Agreement for Tanibirumab, an Anti-VEGFR2/KDR mAb with PharmAbcine

Oct 30, 2014

Affinivax Launches Novel Conjugate Vaccine for Global Impact on Infectious Diseases

Oct 16, 2014

Batu Biologics Awarded Exclusive License from University of California San Diego for Drug That Stimulates Immune System to Kill Cancer

Sep 26, 2014

Sumitomo Dainippon Pharma and SanBio Conclude Joint Development and License Agreement for North America over SB623, Therapy for Stroke

Sep 4, 2014

SELLAS Life Sciences Group Signs Exclusive License Agreement for Global Rights on Development and Commercialization of WT1 Cancer Vaccine with Memorial Sloan Kettering Cancer Center

Aug 15, 2014

Avion Pharmaceuticals, LLC, signs Captisol License Agreement with Ligand Pharmaceuticals to develop four new products

Aug 14, 2014

Ligand Signs Multi-Program Captisol License Agreement with Avion Pharmaceuticals

Jul 1, 2014

CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine

May 5, 2014

FORMA Therapeutics Acquires Covalent Chemistry Platform from Netherlands Cancer Institute

Feb 14, 2014

Acacia Subsidiary Enters into Patent License Agreement with Braeburn Systems LLC

Dec 2, 2013

Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT

Oct 23, 2013

F-star Announces Formation of New Asset-Centric Vehicle, F-star Alpha Ltd, with €9.4m Series A investment

Oct 23, 2013

Alzheon Launches with Veteran Team and Funding to Accelerate Drug Development in Alzheimer’s Disease and Other Neurodegenerative Disorders

Sep 24, 2013

SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.

Aug 7, 2013

Romark And Lupin Reach Strategic Agreement For Promotion And Distribution Of Alinia For Oral Suspension

Jul 26, 2013

CereSpir Incorporated Announces Letter of Intent With Chiesi Farmaceutici SpA, to License Worldwide Development and Commercialization Rights for CHF 5074 to CereSpir

Jul 26, 2013

DGAP-News: CereSpir Incorporated Announces Letter of Intent With Chiesi Farmaceutici SpA, to License Worldwide Development and Commercialization Rights for CHF 5074 to CereSpir

Sep 6, 2012

Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA

Mar 6, 2012

Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004

Feb 13, 2012

OncoPep Enters Exclusive License Agreement with Dana-Farber for Novel Therapeutic Multi-Peptide Vaccine Technology for Hematologic Cancers

Mar 15, 2011

APEIRON Acquires Option to License Rights to Novel Oncology Compounds From Cleveland Clinic

Jan 6, 2011

Cell Medica Signs an Exclusive License Agreement and Strengthens Collaboration With the Center for Cell and Gene Therapy, Baylor College of Medicine

Dec 1, 2010

Ascenta Therapeutics and Ascentage Pharma Sign R&D Collaboration and Regional License Agreements for Two Cancer Programs

May 29, 2010

Bicycle Therapeutics Signs License Agreement with EPFL and Adds SR One and SVLS to Seed Syndicate